Jonah Feldman | Authors

Addition of Darolutamide to ADT and Docetaxel Did not Worsen Safety in mHSPC

May 31, 2022

Adverse effects were found to be similar between patients with metastatic hormone-sensitive prostate cancer who were treated with darolutamide plus androgen deprivation therapy and docetaxel vs androgen deprivation therapy and docetaxel alone.